Xelstrym (Dextroamphetamine) Patent Expiration, LOE Window & CMS Spending

Xelstrym (Dextroamphetamine) by Noven: FDA Orange Book LOE 2042-01-06, 2 AB generics, $1.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNoven
FDA Application & PathwayN215401 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2042-01-06
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$1.3M
2024 Medicare Part D Spend$200K
2024 Medicaid Spend$1.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel